Stomach cancer. clinical significance of the expression of key components of pd-1/pd-l1 immune checkpoint

被引：0
|
作者：
Kovaleva, Olga V. [1 ]
Podlesnaya, Polina A. [1 ]
Gratchev, Alexei N. [1 ]
Chang, Victor L. [2 ]
Ognerubov, Nikolai A. [2 ,3 ]
Kushlinskii, Nikolai E. [1 ]
机构：
[1] Blokhin National Medical Research Center of Oncology, Moscow, Russia
[2] Derzhavin Tambov State University, Tambov, Russia
[3] Tambov Regional Oncological Clinical Dispensary, Tambov, Russia
来源：
Journal of Nonlinear and Variational Analysis | 2021年 / 5卷 / 03期
关键词：
59;
D O I：
10.26442/18151434.2021.1.200749
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：122 / 127
相关论文
共 50 条
  • [21] Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors
    Nakahara, Y.
    Himuro, H.
    Igarashi, Y.
    Kouro, T.
    Higashijima, N.
    Matsuo, N.
    Murakami, S.
    Wei, F.
    Horaguchi, S.
    Tsuji, K.
    Mano, Y.
    Saito, H.
    Azuma, K.
    Naoki, K.
    Sasada, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S614 - S614
  • [22] Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway
    Barclay, Jonathan
    Creswell, Joanne
    Leon, Juan
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (04): : 393 - 399
  • [23] Clinical significance of the tumor expression of PD-L1 in lung cancer.
    De Petris, Luigi
    Ortiz-Villalon, Cristian
    Kis, Lorand
    Tendler, Salomon
    Friesland, Signe
    Lewensohn, Rolf
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities
    Peng, Zikun
    Li, Ming
    Li, Huayi
    Gao, Qinglei
    DRUG DISCOVERY TODAY, 2023, 28 (08)
  • [25] Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer
    AmeliMojarad, Mandana
    AmeliMojarad, Melika
    Cui, Xiaonan
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 244
  • [26] The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia
    Wang, Chuying
    Yu, Jiao
    Fan, Yangwei
    Ma, Ke
    Ning, Jing
    Hu, Yuan
    Niu, Wenxia
    Dong, Xuyuan
    Wu, Yinying
    Li, Enxiao
    Dong, Danfeng
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2019, 49 (04): : 448 - 456
  • [27] Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
    Konstantinidou, Markella
    Zarganes-Tzitzikas, Tryfon
    Magiera-Mularz, Katarzyna
    Holak, Tad A.
    Domling, Alexander
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2018, 57 (18) : 4840 - 4848
  • [28] Expression of PD-1/PD-L1 in lung adenocarcinoma and its clinical significance
    Jian Li
    Yimin Chen
    Oncology and Translational Medicine, 2021, 7 (01) : 15 - 19
  • [29] Macrocyclic Peptide Inhibitor of PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Kuska, Katarzyna
    Skalniak, Lukasz
    Grudnik, Przemyslaw
    Musielak, Bogdan
    Plewka, Jacek
    Kocik, Justyna
    Stec, Malgorzata
    Weglarczyk, Kazimierz
    Sala, Dominik
    Wladyka, Benedykt
    Siedlar, Maciej
    Holak, Tad A.
    Dubin, Grzegorz
    ADVANCED THERAPEUTICS, 2021, 4 (02)
  • [30] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Skalniak, Lukasz
    Zak, Krzysztof M.
    Musielak, Bogdan
    Rudzinska-Szostak, Ewa
    Berlicki, Lukasz
    Kocik, Justyna
    Grudnik, Przemyslaw
    Sala, Dominik
    Zarganes-Tzitzikas, Tryfon
    Shaabani, Shabnam
    Doemling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
12345